Anxioselective profile of glycineB receptor partial agonist, d-cycloserine, in plus-maze-naïve but not plus-maze-experienced mice

European Journal of Pharmacology

Volumn 646, Issue 1-3, 2010, Pages 31-37

  Rodgers, Robert John ^a   Howard, Kimberley ^a   Stewart, Sarah ^a   Waring, Philip ^a   Wright, Fiona Louise ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anxiety; Behavioural selectivity; D cycloserine; Elevated plus maze; GlycineB recognition site; Prior experience

Indexed keywords

CHLORDIAZEPOXIDE; CYCLOSERINE; GLYCINE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ANXIOLYTIC AGENT; GLYCINE RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; EXPERIMENTAL ANIMAL; LONG TERM EXPOSURE; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; TRANQUILIZING ACTIVITY; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; EMOTION;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; CHLORDIAZEPOXIDE; CYCLOSERINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMOTIONS; MALE; MAZE LEARNING; MICE; RECEPTORS, GLYCINE;

EID: 77957015630     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.08.005     Document Type: Article

References (72)

1. Anthony E.W., Nevins M.E. Anxiolytic-like effects of N-methyl-d-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur. J. Pharmacol. 1993, 250:317-324.
2. Barkus C., McHugh S.B., Sprengel R., Seeburg P.H., Rawlins J.N.P., Bannerman D.M. Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur. J. Pharmacol. 2010, 626:49-56.
3. Baron B.M., Harrison B.L., Kehne J.H., Schmidt C.J., van Giersbergen P.L.M., White H.S., Siegel B.W., Senyah Y., McCloskey T.C., Fadayel G.M., Taylor V.L., Murawsky M.K., Nyce P., Salituro F.G. Pharmacological characterization of MDL 105, 519, an NMDA receptor glycine site antagonist. Eur. J. Pharmacol. 1997, 323:181-192.
4. Bergink V., van Megen H.J.G.M., Westenberg H.G.M. Glutamate and anxiety. Eur. Neuropsychopharmacol. 2004, 14:175-183.
5. Bertoglio L.J., Carobrez A.P. Previous experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. Behav. Brain Res. 2000, 108:197-203.
6. Bertoglio L.J., Carobrez A.P. Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats. Psychopharmacology 2003, 170:335-342.
7. Bowery N.G. Glycine-binding sites and NMDA receptors in brain. Nature 1987, 326:338.
8. Carobrez A.P., Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20years on. Neurosci. Biobehav. Rev. 2005, 29:1193-1205.
9. Christmas D., Hood S., Nutt D. Potential novel anxiolytic drugs. Curr. Pharm. Des. 2008, 14:3534-3546.
10. Corbett R., Dunn R.W. Effects of HA-966 on conflict, social interaction, and plus-maze behaviors. Drug Dev. Res. 1991, 24:201-205.
11. Corbett R., Dunn R.W. Effects of 5, 7 dichlrorokynurenic acid on conflict, social interaction and plus-maze behaviors. Neuropharmacology 1993, 32:461-466.
12. Cruz A.P.M., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 1994, 49:171-176.
13. Cryan J.F., Dev K.K. The glutamatergic system as a potential therapeutic target for the treatment of anxiety disorders. Handbook of Anxiety and Fear 2008, Vol. 17:269-301. Elsevier, New York.
14. Danysz W., Parsons C.G. Glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 1998, 50:597-664.
15. Dunn R.W., Flanagan D.M., Martin L.L., Kerman L.L., Woods A.T., Camacho F., Wilmot C.A., Cornfeldt M.L., Effland R.C., Wood P.L., Corbett R. Stereoselective R-(+) enantiomer of HA-966 displays anxiolytic effects in rodents. Eur. J. Pharmacol. 1992, 214:207-214.
16. Emmett M.R., Mick S.J., Cler J.A., Rao T.S., Iyengar S., Wood P.L. Actions of d-cycloserine at the N-methyl-d-aspartate-associated glycine receptor site in vivo. Neuropharmacology 1991, 30:1167-1171.
17. Espejo E.F. Structure of mouse behavior on the elevated plus-maze test of anxiety. Behav. Brain Res. 1997, 86:105-112.
18. Ferreira V.M., Morato G.S. d-cycloserine blocks the effects of ethanol and HA-966 in rats tested in the elevated plus-maze. Alcohol. Clin. Exp. Res. 1997, 21:1638-1642.
19. File S.E. One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology 1990, 100:281-282.
20. File S.E. Behavioural detection of anxiolytic action. Experimental Approaches to Anxiety and Depression 1992, 25-44. Wiley, Chichester. J.M. Elliott, D.J. Heal, C.A. Marsden (Eds.).
21. File S.E., Zangrossi H.J. One-trial tolerance to the anxiolytic actions of the benzodiazepines in the elevated plus-maze, or the development of a phobic state?. Psychopharmacology 1993, 110:240-244.
22. File S.E., Zangrossi H., Viana M., Graeff F.G. Trial 2 in the elevated plus-maze: a different form of fear?. Psychopharmacology 1993, 111:491-494.
23. Flood J.F., Morley J.E., Lanthorn T.H. Effect on memory processing by d-cycloserine, an agonist of the NMDA/glycine receptor. Eur. J. Pharmacol. 1992, 221:249-254.
24. Guastella A.J., Richardson R., Lovibond P.F., Rapee R.M., Gaston J.E., Mitchell P., Dadds M.R. A randomized controlled trial of d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol. Psychiatry 2008, 63:544-549.
25. Ho Y.-J., Hsu L.-S., Wang C.-F., Hsu W.-Y., Lai T.-J., Hsu C.-C., Tsai Y.-F. Behavioural effects of d-cycloserine in rats: the role of anxiety level. Brain Res. 2005, 1043:179-185.
26. Hofmann S.G. Enhancing exposure-based therapy from a translational research perspective. Behav. Res. Ther. 2007, 45:1987-2001.
27. Hofmann S.G., Meuret A.E., Smits J.A.J., Simon N.M., Pollack M.H., Eisenmenger K., Shiekh M., Otto M.W. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry 2006, 63:298-304.
28. Holmes A., Rodgers R.J. Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state?. Pharmacol. Biochem. Behav. 1998, 60:473-488.
29. Holmes A., Rodgers R.J. Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus-maze. Neurosci. Biobehav. Rev. 1999, 23:971-980.
30. Holmes A., Rodgers R.J. Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine. Eur. J. Pharmacol. 2003, 459:221-230.
31. Hood W.F., Compton R.P., Monahan J.B. d-cycloserine: a ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci. Lett. 1989, 98:91-95.
32. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (Lond.) 1987, 325:529-531.
33. Karcz-Kubicha M., Jessa M., Nazar M., Plaznik A., Hartmann S., Parsons C.G., Danysz W. Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology 1997, 36:1355-1367.
34. Kehne J.H., McCloskey T.C., Baron B.M., Chi E.M., Harrison B.L., Whitten J.P., Palfreyman M.G. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur. J. Pharmacol. 1991, 193:283-292.
35. Kleckner N.W., Dingledine R. Requirement for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science (Wash. DC) 1988, 214:835-837.
36. B receptor partial agonist, d-cycloserine, in rats. Pharmacological analysis. Psychopharmacology 2000, 152:224-228.
37. Kotlinska J., Liljequist S. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701, 324. Psychopharmacology 1998, 135:175-181.
38. Kushner M.G., Kim S.W., Donahue C., Thuras P., Adson D., Kotlyar M., McCabe J., Peterson J., Foa E.B. d-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol. Psychiatry 2007, 62:835-838.
39. Lanthorn T.H. d-cycloserine: agonist turned antagonist. Amino Acids 1994, 6:247-260.
40. Lister R.G. The use of the plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
41. Mandell G.J., Petri W.A. Antimicrobial agents: drugs used in the chemotherapy of tuberculosis and leprosy. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996, 1155-1174. McGraw-Hill, New York. J.G. Hartman, L.E. Limbird (Eds.).
42. Mathiasen L.S., Mirza N.R., Rodgers R.J. Strain- and model-dependent effects of chlordiazepoxide, L-838, 417 and zolpidem on anxiety-like behaviours in laboratory mice. Pharmacol. Biochem. Behav. 2008, 90:19-36.
43. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 2003, 70:83-244.
44. Monahan J.B., Handelmann G.E., Hood W.F., Cordi A.A. d-cycloserine, a positive modulator of N-methyl-d-apsartate receptor, enhances performance tasks in rats. Pharmacol. Biochem. Behav. 1989, 34:649-653.
45. Myers K.M., Carlezon W.A. d-cycloserine facilitates extinction of naloxone-induced conditioned place aversion in morphine-dependent rats. Biol. Psychiatry 2010, 67:85-87.
46. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biol. Psychiatry 2008, 63:1118-1126.
47. Nunnink M., Davenport R.A., Ortega B., Houpt T.A. d-cycloserine enhances conditioned taste aversion learning in rats. Pharmacol. Biochem. Behav. 2007, 87:321-330.
48. Otto M.W., Smits J.A.J., Reese H.E. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin. Psychol. Sci. Prac. 2005, 12:72-86.
49. Otto M.W., Tolin D.F., Simon N.M., Pearlson G.D., Basden S., Meunier S.A., Hofmann S.G., Eisenmenger K., Pollack M.H. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol. Psychiatry 2010, 67:365-370.
50. Parnas A.S., Weber M., Richardson R. Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats. Neurobiol. Learn. Mem. 2005, 83:224-231.
51. Popik P., Wrobel M., Nowak G. Chronic treatment with antidepressants affects glycine/NMDA receptor function: behavioral evidence. Neuropharmacology 2000, 39:2278-2287.
52. Priestley T., Kemp J.A. Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-d-aspartate receptor complex. Mol. Pharmacol. 1994, 46:1191-1196.
53. Przegalinski E., Tatarczynska E., Deren-Wesolek A., Chojnacka-Wojcik E. Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Pharmacol. Biochem. Behav. 1996, 54:73-77.
54. B receptors. Pharmacol. Biochem. Behav. 1999, 64:461-466.
55. Quartermain D., Mower J., Rafferty M.F., Herting R.L., Lanthorn T.H. Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention. Eur. J. Pharmacol. 1994, 257:7-12.
56. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., Hodges L., Davis M. Cognitive enhancers as adjuncts to psychotherapy. Arch. Gen. Psychiatry 2004, 61:1136-1144.
57. Richardson R., Ledgerwood L., Cranney J. Facilitation of fear extinction by d-cycloserine: theoretical and clinical implications. Learn. Mem. 2004, 11:510-516.
58. Rodgers R.J., Cole J.C. An ethological analysis of chlordiazepoxide and bretazenil (Ro16-6028) in the murine elevated plus-maze. Behav. Pharmacol. 1993, 4:573-580.
59. Rodgers R.J., Johnson N.J.T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 1995, 52:297-303.
60. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 1993, 113:237-242.
61. Rodgers R.J., Johnson N.J.T., Cole J.C., Dewar C.V., Kidd G.R., Kimpson P.H. Plus-maze retest profile in mice: importance of initial stages of trial 1 and response to post-trial cholinergic receptor blockade. Pharmacol. Biochem. Behav. 1996, 54:41-50.
62. Rodgers R.J., Haller J., Halasz J., Mikics E. 'One-trial sensitisation' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci. 2003, 17:1279-1286.
63. 1) receptor antagonist, NKP608, is devoid of anxiolytic-like activity in the mouse elevated plus-maze. Behav. Brain Res. 2004, 154:183-192.
64. Roy V., Chapillon P., Jeljeli M., Caston J., Belzung C. Free versus forced exposure to an elevated plus-maze: evidence for new behavioral interpretations during test and retest. Psychopharmacology 2009, 203:131-141.
65. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 1993, 33:463-469.
66. Trullas R., Jackson B., Skolnick P. Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors. Pharmacol. Biochem. Behav. 1989, 34:313-316.
67. Walker D.L., Ressler K.J., Lu K.-T., Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats. J. Neurosci. 2002, 22:2343-2351.
68. Weiss, S.M., 1995. Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the Tawny Owl. PhD thesis, University of Leeds.
69. Wiley J.L., Cristello A.F., Balster R.L. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur. J. Pharmacol. 1995, 294:101-107.
70. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., Cannistraro P., Jenike M.A., Rauch S.L. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am. J. Psychiat. 2008, 165:335-341.
71. Winslow J.T., Insel T.R., Trullas R., Skolnick P. Rat pup isolation calls are reduced by functional antagonists of the NMDA receptor complex. Eur. J. Pharmacol. 1990, 190:11-21.
72. Wood P.L. The co-agonist concept: is the NMDA-asosciated glycine receptor saturated in vivo?. Life Sci. 1995, 57:301-310.